MXPA06015172A - Injectable solution of progesterone extended-release for veterinary use and process for obtaining the same. - Google Patents
Injectable solution of progesterone extended-release for veterinary use and process for obtaining the same.Info
- Publication number
- MXPA06015172A MXPA06015172A MXPA06015172A MXPA06015172A MX PA06015172 A MXPA06015172 A MX PA06015172A MX PA06015172 A MXPA06015172 A MX PA06015172A MX PA06015172 A MXPA06015172 A MX PA06015172A
- Authority
- MX
- Mexico
- Prior art keywords
- progesterone
- release
- prolonged
- veterinary use
- injectable solution
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 152
- 239000000186 progesterone Substances 0.000 title claims abstract description 76
- 229960003387 progesterone Drugs 0.000 title claims abstract description 74
- 229940102223 injectable solution Drugs 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 11
- 230000008569 process Effects 0.000 title claims abstract description 11
- 238000013265 extended release Methods 0.000 title abstract description 3
- 229940088597 hormone Drugs 0.000 claims abstract description 21
- 239000005556 hormone Substances 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 230000001850 reproductive effect Effects 0.000 claims abstract description 11
- 241000894007 species Species 0.000 claims abstract description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 230000002035 prolonged effect Effects 0.000 claims description 33
- 238000002425 crystallisation Methods 0.000 claims description 14
- 230000008025 crystallization Effects 0.000 claims description 14
- 229940090319 progesterone injectable solution Drugs 0.000 claims description 12
- 244000144972 livestock Species 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 150000003146 progesterones Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 abstract description 16
- 230000035558 fertility Effects 0.000 description 10
- 239000007943 implant Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 3
- 230000012173 estrus Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003688 hormone derivative Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960001207 micronized progesterone Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- IWSXBCZCPVUWHT-VIFKTUCRSA-N [(8r,9s,10r,11s,13s,14s,17r)-17-acetyl-11,13-dimethyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound O=C1CC[C@@H]2[C@H]3[C@@H](C)C[C@]4(C)[C@](C(C)=O)(OC(C)=O)CC[C@H]4[C@@H]3CCC2=C1 IWSXBCZCPVUWHT-VIFKTUCRSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229950010960 norgestomet Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229940046999 synovex Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention is intended for facilitating and improving the reproductive handle and control of animals from different cattle species, and mainly it is intended for improving the means used to control and manipulate the reproductive cycles of animals from different breeds and species; and more particularly it refers to an extended-release subcutaneous veterinary injectable solution for the reproductive handle and control of animals from different species and to the process for obtaining the same, which is characterised in that it comprises a mixture of progesterone; the process for obtaining the injectable veterinary solution comprises the steps of mixing the three physical states of the progesterone hormone with the excipients required for obtaining a solution.
Description
INJECTABLE SOLUTION OF PROGESTERONE OF PROLONGED RELEASE FOR VETERINARY USE AND PROCESS OF OBTAINING THE SAME
FIELD OF THE INVENTION
The present invention is related to the management and reproductive control of animals of different livestock species, in particular it refers to the means used to control and manipulate the reproductive cycles of various species and breeds of animals. More specifically it is referred to an injectable solution for prolonged-release progesterone veterinary use to facilitate and improve the management and reproductive control of animals of different species.
BACKGROUND OF THE INVENTION
It is well known that in the management of livestock is carried out a manipulation and control of the reproductive cycles of females of various species of animals of economic interest and food for the human being, in order to control and synchronize the zeal try to increase the fertility of the females. Thus, there is an infinity of studies in this respect in
those that analyze the release of hormones through the application of ovules or subcutaneous implantation, or also with the use of progesterone injections of normal release.
There are progestogen releasers (which is a substance with a similar action to progesterone that favors the normal course of pregnancy) for example the products that are commercially called "CRESTAR®" and "SINCROMATE®" through implants combined with injectable solutions that they comprise the compounds of "norgestomet" and "estradiol valerate", there are other products such as the commercially named "CIDR®" which releases prolonged progesterone but is of vaginal application and the functions for which it is recommended is not to favor the fertility.
There are also other implants of progesterone and estradiol of subcutaneous application "SYNOVEX B®" used for the fattening of cattle, these are made of several pills that are applied subcutaneously directly without the use of implants as vehicles.
The current implants with progestagens and the intravaginal progesterone releaser have as a function the synchronization and induction of heat in cows, but not as favoring fertility.
However, with the application of this type of products with progestagens that are not natural and are much more powerful, part of these hormones (synthetic hormones not natural) pass into the milk or are deposited in the meat, so these hormones They go directly to the final consumer that directly affect human health and the effects of these hormones on people can have important consequences.
Currently a veterinary implant has been developed in animals that allows a prolonged release of hormones specifically from the natural hormone progesterone, which also avoids the risk of consuming powerful synthetic hormones that affect human health, registered in the patent office, by this same Author.
There are also solutions of Progesterone, "PROGESTERONA®" that are applied to animals, but do not have a prolonged release for days of the active substance, that is, they release it in normal form with circulation at plasma levels of 36 to 48 hrs.
Other products on the market with injectable progesterone combined with vitamins, "PROGESVIT A-E®", "PROGESTYN®" and "PROGESVIT A-E®" that are applied to animals, without prolonged release to more than 48 hrs.
In order to provide an injectable solution of natural progesterone of easy handling that allows the release in prolonged form, to improve the fertility of the females in heat, it was that the injectable solution of the present invention was developed.
OBJECTIVES OF THE INVENTION
The main object of the present invention is to make available a prolonged release progesterone subcutaneous injectable solution for veterinary use that allows the prolonged release of the natural progesterone hormone.
Another objective of the invention is to make available said subcutaneous prolonged-release progesterone injectable solution for veterinary use, which also allows the increase of serological levels of progesterone in a period of time to create favorable conditions that allow greater probability of females Be pregnant.
Yet another objective of the present invention is to make available said prolonged-release progesterone injectable solution for veterinary use, which also economically helps the livestock production of different species.
Still another objective of the invention is to provide an injectable solution of prolonged release progesterone for veterinary use, which also facilitates, improves and makes more efficient and economical the management and reproductive control of females of different species of animals of economic interest and food for the human being
Still another object of the invention is to make available said prolonged-release progesterone injectable solution for veterinary use, which also helps to solve livestock fertility problems such as anestros or prolonged open periods.
Still another objective of the invention is to make available said injectable prolonged-release progesterone solution for veterinary use, which also helps to improve the management of cattle through the synchronization of estrus.
Still another objective is to make available a process for the elaboration of an injectable solution of prolonged release progesterone for veterinary use.
Still another object of the invention is to make said process available for the elaboration of an injectable solution of prolonged-release progesterone for veterinary use, which
also be economical, simple and easy to execute.
Other objects and advantages of the present invention may be apparent from the study of the following description and the accompanying drawings for illustrative purposes only and not limitation.
DESCRIPTION OF THE INVENTION
In general, the prolonged release progesterone injectable solution for veterinary use for the greater fertility of cattle females of different species, according to the present invention, is composed of a mixture that is composed of micronized progesterone, progesterone crystallized in different forms and in different physical states, an emulsifying substance in particular a water-soluble and hygroscopic polymer consisting of KOLUGON® 90 F polyvinylpyrrolidone and cbp excipient vehicles which give stability to the active ingredient and thickness to the solution; the progesterone amounts will be based on the needs and the doses to be applied to the females.
Quantitatively the composition comprises: a) 5 mg of micronized natural progesterone; b) 20 mg of
slower crystallization progesterone, called P4; c) 150 mg of slow crystallization progesterone, called P5; d) 60 mg of an emulsifier consisting of polyvinylpyrrolidone KOLLIGON® 90 F and e) 2 ml of cbp excipients which is selected from injectable water or from oleic acid.
The solubility of progesterone decreases with a different crystallization, so three types of progesterone with different degrees of crystallization are combined.
The solubility of progesterone increases or decreases according to the crystals that form it. The commercially available micronized progesterone melts and when it cools it crystallizes (it goes from the liquid to the solid state) it is made in a warmer environment than the environment, which delays the crystallization and allows the junctions between the progesterone molecules save more energy and be more insoluble in the body of the animal. Progesterone takes 6 - 9 min. to crystallize.
The composition was obtained after multiple studies that resulted in the ideal composition taking into account that the hormone progesterone naturally and dosed in adequate amounts does not affect human health; and is naturally eliminated by a metabolic pathway in the liver
favoring and increasing the probability of fertilization.
The release of the hormone is by gradients of concentration, and the solubility capacity of the active substances, and by its subcutaneous presence inside the animal, the titrated liquids, enzymes and other chemical compounds that intervene, allow partial dissolution and incorporation into the body. bloodstream that directs them to their metabolic pathway. Now the release is also a function of the metabolism of females.
The amount of the hormone progesterone is important, given that in small amounts, the concentrations obtained in the blood of animals will be lower and therefore the ovarian cycle and the uterus of the female where the embryo is implanted will not be affected, and could even be harmful to fertility.
In dairy cattle for example, it must be at least so that the females have a good fertility, amounts of 4.5 mg of the hormone per my serum and the higher the concentration the greater the fertility; however, it would affect the normal amount of the hormone in the milk and may go out of the norm.
The process of obtaining an injectable solution of prolonged-release progesterone for veterinary use, of
according to the present invention comprises the steps of: I) mixing progesterone in three different physical states, micronized and crystallized into two different degrees of crystallization (slow and slow); II) mix with emulsifiers; III) mix with a vehicle.
To obtain the crystallized progesterone, the following steps are carried out: 1) the progesterone is melted; 2) it crystallizes at different temperatures to obtain two salts with different crystallization times, with temperature controlled environments from 80 and 25 degrees Celsius; 3) the crystallized progesterone is milled and sieved with pharmaceutical mesh 70 so that the parts obtained are capable of being injected by means of a number 16 or 14 needle; 4) the defined amount in the slowly crystallizing progesterone composition is weighed, the slower crystallization progesterone is weighed and mixed with natural progesterone.
The emulsifying substance protects the active ingredient and allows the mixture of progesterones in the different states and degrees of crystallization without precipitating quickly when the excipient or vehicle is applied so that it forms the emulsion and can be injected.
Subcutaneous application favors a slow absorption of the active substance.
Such injectable solution for prolonged release progesterone veterinary use are widely required and can be applied in dairy cattle where fertility problems occur, this is a way to try to improve livestock in this regard; it is therefore intended to improve the reproduction of livestock, which will make more profits for dairymen, more conservation of genetically valuable livestock for less waste, better milk quality by somatic cells and perhaps more possibilities for better product prices.
The prolonged release progesterone injectable solution for veterinary use also works improving the nutrition of the embryo in the first 15 days of life and improves reproduction by 66%, ie in case of cattle, the repetitive cows are loaded in 66% more with the implant.
Table I, shown below, shows the results of biological behavior tests in cows with two exact 21-day cycles prior to treatment. Different amounts of the injectable solution of progesterone for prolonged-release veterinary use were applied to the cows under treatment; on day 17 of your cycle, which is when the levels of
progesterone begin to descend to start a new cycle, taking as day 1 the day of the previous heat.
Table I
The answer that was had in these tests, is based on the already known functions of the progesterone that enters the female is to suspend the sexual manifestations of heat or estrus, they show us with the delay of the presentation of heat, the days that there were high levels of progesterone, after prolonged-release progesterone injection.
The foregoing is also based on the fact that progesterone is completely eliminated from the organism of a cow in a period
of time of 22-36 minutes, which suggests that to achieve levels that manifest in the behavior of the cow, it must be constantly releasing exogenous progesterone.
In order to better understand the characteristics of the invention, the present description is accompanied, as an integral part thereof, by the drawings which are illustrative but not limitative, which are described below in the preferred embodiment.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 and only shows a graph illustrating the sexual behavior of cows based on the evolution of the concentration of the hormone progesterone as a result of the application of the injectable solution, in accordance with the present invention.
For a better understanding of the invention, a detailed description will be made of some of the modalities thereof, shown in the drawings that are attached to the present description for non-limiting illustrative purposes.
DETAILED DESCRIPTION OF THE INVENTION
The characteristic details of the progesterone extended-release injectable solution for veterinary use are clearly shown in the following description and in the accompanying illustrative drawings, the same reference signs serving to indicate the same parts.
With reference to Figure 1, which shows a graph illustrating the sexual behavior of cows based on the evolution of the concentration of the hormone progesterone as a result of the application of the injectable solution, in accordance with the present invention. In this figure, the evolution of the release of progesterone is shown once the progesterone injectable solution has been applied in a cow on the 17th day of its estrous cycle, taking as day 1 the day of the previous estrus.
In the graph you can see how progesterone is released from a lower concentration in the first days to a higher concentration in recent days.
Thus the hormone, depending on the amount injected and weight of the female, is gradually released in a span that covers approximately 5-21 days and the concentrations of this in the blood of the females will be a function of their metabolism and
other factors.
In any case, it is intended to have an injectable solution for prolonged-release progesterone for veterinary use with amounts ranging from 100 mg to 500 mg; that will be applied in the females depending on the conditions of each species and physiological state of the female, the requirements of concentration of the hormone and the time that is necessary to maintain high levels of that hormone in a female, for example a solution Injectable veterinary with less hormones may be used in repetitive females that need more inseminations or bull mounts to get pregnant; The injectable veterinary solution with the highest amount of hormones can be used in fresh-born females.
The invention has been sufficiently described so that a person with average skill in the art can reproduce and obtain the results that we mentioned in the present invention. However, any person skilled in the art who is competent in the present invention may be able to make modifications not described in the present application, however, if for the application of these modifications in a certain structure or in the manufacturing process thereof, the subject matter claimed in the following claims is required, said structures should be understood within the scope of the invention.
Claims (8)
1. - Prolonged-release progesterone injectable solution for veterinary use, characterized in that it comprises crystallized progesterone with a physical state different from the normal presentation.
2. - Prolonged-release progesterone injectable solution for veterinary use, according to claim 1, characterized in that it is composed of micronized natural progesterone, progesterone crystallized in different degrees and in different physical states, an emulsifying substance and an excipient.
3. - Prolonged-release progesterone injectable solution for veterinary use, according to claim 2, characterized in that said emulsifying substance consists of polyvinylpyrrolidone.
4. - Prolonged-release progesterone injectable solution for veterinary use, according to claim 2, characterized in that said excipient is selected from injectable water or from oleic acid.
5. - Prolonged-release progesterone injectable solution for veterinary use, according to claims 1 and 2, characterized in that the crystallized progesterone is progesterone that slowly crystallizes called P5 and slower crystallization progesterone called P4.
6. Prolonged-release progesterone injectable solution for veterinary use, according to claims 1 to 4, characterized in that it comprises quantitatively a) 5 mg of micronized natural progesterone; b) 20 mg of slower crystallization progesterone, called P4; c) 150 mg of slow crystallization progesterone, called P5; d) 60 mg of an emulsifier consisting of polyvinylpyrrolidone KOLLIGON® 90 F and e) 2 ml of cbp excipients which is selected from injectable water or from oleic acid.
7. - A process for obtaining an injectable solution of prolonged release progesterone for veterinary use, characterized in that it comprises the steps of: I) mixing progesterone in three different physical states, micronized and crystallized in two different degrees of crystallization (slow and slower) ); II) mix with emulsifiers the three states physicals of progesterone; III) mix with a vehicle.
8. - A process for obtaining an injectable solution of prolonged release progesterone for veterinary use, according to claim 7, characterized in that the following steps are performed to obtain the crystallized progesterone: 1) melting the progesterone; 2) crystallize the melted progesterone at different temperatures to obtain two salts with different crystallization times, with temperature controlled environments from 80 and 25 degrees centigrade; 3) grinding and straining the crystallized progesterone with pharmaceutical mesh 70 to obtain particle size capable of being injected; 4) weigh the pre-established amounts to mix them with natural progesterone. SUMMARY The present invention is related to facilitating and improving the management and reproductive control of animals of different livestock species, in particular it is referred to improve the means used to control and manipulate the reproductive cycles of various species and breeds of animals; more specifically, it refers to a prolonged-release subcutaneous injectable veterinary solution for the management and reproductive control of animals of different species and to the process of obtaining same; characterized in that it comprises a mixture of progesterones; the process of obtaining the injectable veterinary solution comprises the steps of mixing the three physical states of the hormone progesterone with the excipients to obtain a solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA06015172 MXPA06015172A (en) | 2006-12-20 | 2006-12-20 | Injectable solution of progesterone extended-release for veterinary use and process for obtaining the same. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA06015172 MXPA06015172A (en) | 2006-12-20 | 2006-12-20 | Injectable solution of progesterone extended-release for veterinary use and process for obtaining the same. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06015172A true MXPA06015172A (en) | 2009-04-17 |
Family
ID=41127537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06015172 MXPA06015172A (en) | 2006-12-20 | 2006-12-20 | Injectable solution of progesterone extended-release for veterinary use and process for obtaining the same. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MXPA06015172A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10898432B2 (en) | 2015-12-18 | 2021-01-26 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
-
2006
- 2006-12-20 MX MXPA06015172 patent/MXPA06015172A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10898432B2 (en) | 2015-12-18 | 2021-01-26 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leboeuf et al. | Efficacy of two types of vaginal sponges to control onset of oestrus, time of preovulatory LH peak and kidding rate in goats inseminated with variable numbers of spermatozoa | |
| Criscuolo-Urbinati et al. | The administration of exogenous prostaglandin may improve ovulation in pacu (Piaractus mesopotamicus) | |
| CN101869221B (en) | Feed additive for improving reproductive capacity of sow and preparation method thereof | |
| US20060051391A1 (en) | Device for the controlled administration of substances to be inserted in a body cavity | |
| ES2893121T3 (en) | Formulations and methods to control the reproductive cycle and ovulation | |
| Chatdarong et al. | The effect of ACTH stimulation on cortisol and progesterone concentrations in intact and ovariohysterectomized domestic cats | |
| MXPA06015172A (en) | Injectable solution of progesterone extended-release for veterinary use and process for obtaining the same. | |
| WO2010143101A1 (en) | Use of 1,25-dihydroxyvitamine d3 glycoside in lactating animals. | |
| CN109498557A (en) | A kind of cloprostenol sodium injection and preparation method thereof | |
| Nathanielsz | Fetal programming: how the quality of fetal life alters biology for a lifetime | |
| Nak et al. | The effects of Ovsynch, Ovsynch with progestin and progestin plus double TAI on pregnancy rates in unobserved oestrus dairy cows and heifers | |
| AU2006200870B2 (en) | Element deficiency and prevention treatment | |
| AU2009230806B2 (en) | Improved medicament formulation | |
| AU2006225364B2 (en) | Injection formulation containing the elements selenium and iodine | |
| RU2790575C1 (en) | Method for production of combined antihelminth drug for prevention and treatment of fish cestodiasis | |
| RU2765838C1 (en) | Remedy for the treatment of postpartum mastitis and endometritis in cows | |
| Daoud et al. | GDF-9 gene expression, oocyte quality, hematological and biochemical profiles affected by feed restriction as a biostimulant method on rabbits' fertility | |
| Noiret et al. | Sex-specific central regulation of reproductive activity revealed by the use of deslorelin in the grey mouse lemur, Microcebus murinus | |
| MXPA06000375A (en) | Progesterone extended-release subcutaneous veterinary implant and process for obtaining the same. | |
| BE1019408A5 (en) | USE OF 1,25-DIHYDROXYVITAMIN D3 GLYCOSIDE IN MILK-GIVING ANIMALS. | |
| JP2007039355A (en) | Oily preparation containing physiologically active substance | |
| RU2616252C2 (en) | Method of controlling sexual behaviour of male mammals | |
| JP2007254434A (en) | Maturation- and ovulation-inducing method for sevenband grouper by lhrha injection administration using cacao butter oily preparation | |
| BR102022018653A2 (en) | CALCIUM METABOLISM ADAPTER FOR PREVENTION OF HYPOCALCEMIA IN DAIRY COWS | |
| AU2022334280A1 (en) | Methods for reproductive management of sheep and goats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |